"The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dalbavancin 500 mg (Xydalba, Durata Therapeutics) for acute bacterial skin and skin structure infections (ABSSSI) in ad"...
TEMOVATE Gel (clobetasol propionate gel) is a superhigh potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituftary-adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended.
DOSAGE AND ADMINISTRATION
Apply a thin layer of TEMOVATE Gel (clobetasol propionate gel) to the affected skin areas twice daily and rub in gently and completely (see INDICATIONS AND USAGE).
TEMOVATE Gel (clobetasol propionate gel) is a super-high potency topical corticosteroid; therefore, treatment should be limited to 2 consecutive weeks and amounts greater than 50 g/week should not be used.
TEMOVATE Gel (clobetasol propionate gel) should not be used with occlusive dressings.
Geriatric Use: In studies where geriatric patients (65 years of age or older, see PRECAUTIONS) have been treated with TEMOVATE Gel (clobetasol propionate gel) , safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.
TEMOVATE Gel (clobetasol propionate gel) , 0.05% is supplied in 15-g (NDC 0173-0455-01), 30-g (NDC 0173-0455-02), and 60-g (NDC 0173-0455-03) tubes. Store between 2° and 30°C (36° and 86°F).
Glaxo Wellcome Inc. Research Triangle Park, NC 27709, July 2000. FDA rev date: 4/2/2003This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/24/2008
Additional Temovate Gel Information
Report Problems to the Food and Drug Administration
Find out what women really need.